KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Retained Earnings for 18 consecutive years, with -$6.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings rose 11.55% year-over-year to -$6.5 billion; the TTM value through Mar 2026 reached -$6.5 billion, up 11.55%, while the annual FY2025 figure was -$6.7 billion, 19317.47% down from the prior year.
  • Retained Earnings hit -$6.5 billion in Q1 2026 for Alnylam Pharmaceuticals, up from -$6.7 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$21.8 million in Q3 2025 and bottomed at -$7.3 billion in Q1 2025.
  • Average Retained Earnings over 5 years is -$3.9 billion, with a median of -$6.0 billion recorded in 2022.
  • Year-over-year, Retained Earnings skyrocketed 99.64% in 2024 and then plummeted 19317.47% in 2025.
  • Alnylam Pharmaceuticals' Retained Earnings stood at -$44.7 million in 2022, then skyrocketed by 47.65% to -$23.4 million in 2023, then crashed by 47.67% to -$34.5 million in 2024, then tumbled by 19317.47% to -$6.7 billion in 2025, then grew by 3.07% to -$6.5 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$6.5 billion, -$6.7 billion, and -$21.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.